Global Wealth Management Investment Advisory Inc. Acquires New Shares in CVS Health Corporation $CVS

Global Wealth Management Investment Advisory Inc. bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the 3rd quarter, HoldingsChannel reports. The firm bought 60,937 shares of the pharmacy operator’s stock, valued at approximately $4,594,000.

Several other large investors have also modified their holdings of the business. SOA Wealth Advisors LLC. boosted its stake in shares of CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares in the last quarter. Symmetry Partners LLC lifted its holdings in CVS Health by 2.5% during the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock worth $439,000 after buying an additional 141 shares during the period. Harbor Capital Advisors Inc. boosted its position in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 142 shares in the last quarter. HF Advisory Group LLC increased its holdings in shares of CVS Health by 2.9% in the 3rd quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock valued at $393,000 after acquiring an additional 145 shares during the period. Finally, United Asset Strategies Inc. raised its position in shares of CVS Health by 1.8% in the 3rd quarter. United Asset Strategies Inc. now owns 8,852 shares of the pharmacy operator’s stock worth $667,000 after acquiring an additional 154 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein raised its price target to $91 and reaffirmed a Market Perform rating, signaling incremental analyst support for a higher valuation and helping sentiment on the name. Bernstein raises PT on CVS Health (CVS) to $91, reiterates ‘market perform’ rating
• Positive Sentiment: Gilead said its new HIV prevention shot has been added to CVS’s drug coverage lists for commercial plans — a win for pharmacy and PBM revenue mix and utilization that could lift prescription volume and margins. Gilead’s new HIV prevention shot added to CVS’s drug coverage lists, CEO says
• Positive Sentiment: High-profile media commentary (Jim Cramer) highlighting CEO Karen Lynch/management execution (“Joyner’s money”) is boosting investor confidence in leadership and strategy. Jim Cramer on CVS CEO: “Joyner’s Money”
• Neutral Sentiment: Research outlets (Zacks) are publishing favorable screens on CVS as a top-ranked value and momentum stock and highlighting strong earnings surprise history — these pieces raise investor attention but are informational unless followed by concrete catalyst. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Neutral Sentiment: Zacks coverage also notes heavy investor searches and discusses the company’s likelihood of beating upcoming estimates — increased attention can boost liquidity and short-term momentum but isn’t a direct fundamental change. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Negative Sentiment: An Illinois risk pool has sued Eli Lilly, CVS and UnitedHealth over insulin pricing — this litigation adds regulatory and legal risk, potential damages and reputational downside that could pressure the stock if claims escalate or lead to material fines. Illinois risk pool sues Eli Lilly, CVS, UnitedHealth over insulin pricing

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CVS. Evercore ISI lifted their target price on CVS Health from $85.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Robert W. Baird raised their price target on shares of CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Mizuho increased their target price on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. raised their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.86.

CVS Health Stock Up 0.3%

CVS stock opened at $80.63 on Wednesday. The stock has a market capitalization of $102.36 billion, a PE ratio of 212.20, a price-to-earnings-growth ratio of 0.74 and a beta of 0.48. CVS Health Corporation has a 52 week low of $50.14 and a 52 week high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. The firm has a 50 day moving average of $78.78 and a 200 day moving average of $74.10.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date is Thursday, January 22nd. CVS Health’s payout ratio is presently 700.00%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.